Published January 13, 2014 | Version v1
Journal article

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases

  • 1. Department of Radiation Oncology, Seoul National University Bundang Hospital, 166 Gumiro, Bundanggu, Seongnamsi Kyeonggido (Korea, Republic of)
  • 2. Cancer Research Institute, Seoul National University 101 Daehak-ro, Jongno-gu, Seoul 110-779 (Korea, Republic of)

Description

Despite aggressive treatment with radiation therapy and concurrent adjuvant temozolomide (TMZ), glioblastoma multiform (GBM) still has a dismal prognosis. We aimed to identify strategies to improve the therapeutic outcome of combined radiotherapy and TMZ in GBM by targeting pro-survival signaling from the epidermal growth factor receptor (EGFR). Glioma cell lines U251, T98G were used. Colony formation, DNA damage repair, mode of cell death, invasion, migration and vasculogenic mimicry as well as protein expression were determined. U251 cells showing a low level of methyl guanine transferase (MGMT) were highly responsive to the radiosensitizing effect of TMZ compared to T98G cells having a high level of MGMT. Treatment with a dual inhibitor of Class I PI3K/mTOR, PI103; a HSP90 inhibitor, 17-DMAG; or a HDAC inhibitor, LBH589, further increased the cytotoxic effect of radiation therapy plus TMZ in U251 cells than in T98G cells. However, treatment with a mTOR inhibitor, rapamycin, did not discernibly potentiate the radiosensitizing effect of TMZ in either cell line. The mechanism of enhanced radiosensitizing effects of TMZ was multifactorial, involving impaired DNA damage repair, induction of autophagy or apoptosis, and reversion of EMT (epithelial-mesenchymal transition). Our results suggest possible strategies for counteracting the pro-survival signaling from EGFR to improve the therapeutic outcome of combined radiotherapy and TMZ for high-grade gliomas

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-14-17; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910677

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
14
Journal Page Range
p. 17
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46123915
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
DNA DAMAGES; GLIOMAS; GROWTH FACTORS; RADIOTHERAPY; REPAIR
Descriptors DEC
DISEASES; MEDICINE; MITOGENS; NEOPLASMS; NERVOUS SYSTEM DISEASES; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; PROTEINS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2014 Choi et al.
Notes
PMCID: PMC3910677; PUBLISHER-ID: 1471-2407-14-17; PMID: 24418474; OAI: oai:pubmedcentral.nih.gov:3910677; licensee BioMed Central Ltd.